PASTOR, Yadira; REYNARD, Olivier; IAMPIETRO, Mathieu; SURENAUD, Mathieu; PICARD, Florence; EL JAHRANI, Nora; LEFEBVRE, Cecile; HAMMOUDI, Adele; DUPATY, Lea; BRISEBARD, Elise; REYNARD, Stephanie; MOUREAUX, Elodie; MOROSO, Marie; DURAND, Stephanie; GONZALEZ, Claudia; AMURRI, Lucia; GALLOUET, Anne-Sophie; MARLIN, Romain; BAIZE, Sylvain; CHEVILLARD, Eve; RAOUL, Herve; HOCINI, Hakim; CENTLIVRE, Mireille; THIEBAUT, Rodolphe; HORVAT, Branka; GODOT, Veronique; LEVY, Yves; CARDINAUD, Sylvain

doi:10.1016/j.xcrm.2024.101467

Idioma

Article de revue

Este ítem está publicado en

Cell Reports Medicine. 2024-03-19, vol. 5, n° 3, p. 101467

Resumen en inglés

Nipah virus (NiV) has been recently ranked by the World Health Organization as being among the top eight emerging pathogens likely to cause major epidemics, whereas no therapeutics or vaccines have yet been approved. We report a method to deliver immunogenic epitopes from NiV through the targeting of the CD40 receptor of antigen-presenting cells by fusing a selected humanized anti-CD40 monoclonal antibody to the Nipah glycoprotein with conserved NiV fusion and nucleocapsid peptides. In the African green monkey model, CD40.NiV induces specific immunoglobulin A (IgA) and IgG as well as cross-neutralizing responses against circulating NiV strains and Hendra virus and T cell responses. Challenge experiments using a NiV-B strain demonstrate the high protective efficacy of the vaccine, with all vaccinated animals surviving and showing no significant clinical signs or virus replication, suggesting that the CD40.NiV vaccine conferred sterilizing immunity. Overall, results obtained with the CD40.NiV vaccine are highly promising in terms of the breadth and efficacy against NiV.< Leer menos

Palabras clave en inglés

CD40-targeting vaccine

Henipavirus

Nipah virus

cross-neutralizing responses

Dendritic cell-based vaccine

Epitope mapping

Germinal center reaction

Neutralizing antibodies

Prophylactic vaccine

Sterilizing immunity

URI

https://oskar-bordeaux.fr/handle/20.500.12278/199674

DOI

http://dx.doi.org/10.1016/j.xcrm.2024.101467

Proyecto ANR

Initiative for the creation of a Vaccine Research Institute

Centros de investigación

Bordeaux Population Health Research Center (BPH) - UMR 1219

Ver/Abrir

Metadatos

Compartir este ítem

Licencia de uso del documento

A vaccine targeting antigen-presenting cells through CD40 induces protective immunity against Nipah disease